WORD COUNT: 229 24 25 TEXT WORD COUNT: 3,409 26 27 (ZIKV) epidemic in the Americas and the Caribbean 49 demonstrates that clinical assays to detect, distinguish, and characterize immune 50 responses to flaviviral infections are needed. ZIKV and dengue virus (DENV) are 51 mosquito-transmitted flaviviruses sharing overlapping geographical distribution and 52
INTRODUCTION
6 reduction neutralization tests (PRNTs) (11, (13) (14) (15) (16) . These tests, however, are 116 challenged in their ability to confirm infection in individuals with multiple flaviviral 117 infections especially during the acute and early convalescent phases. Several studies 118 have also shown that most dengue-immune sera or DENV E monoclonal antibodies 119 cross-react to ZIKV, but contain limited cross-neutralization activity and can instead 120 enhance ZIKV infection, known as antibody-dependent enhancement (ADE) (17) (18) (19) (20) (21) (22) . In 121 contrast, recent studies reported antibodies to ZIKV nonstructural protein 1 (NS1) were 122 able to discriminate infections by these viruses (23, 24) . We previously showed that 123 combinations of DENV and ZIKV NS1-based enzyme-linked immunosorbent assays 124 (ELISAs) were capable of distinguishing confirmed cases with past and present flaviviral 125 infections including primary DENV (pDENV) and ZIKV (pZIKV), ZIKV with primary 126 DENV (ZIKVwpDENV), and secondary DENV (sDENV) infections (12). These ELISAs 127 are applicable for routine serological tests for DENV and ZIKV as well useful in 128 retrospective studies to identify individuals with primary and multiple flaviviral infections. 129 7 responses against DENV target nonstructural (NS) proteins such as NS3, NS4B, and 139 NS5, ZIKV-specific CD8 + T cell responses target the structural proteins, capsid (C), 140 premembrane (prM), and E (10, 26) . We previously developed a modified anthrax toxin 141 (LFn)-based enzyme-linked immunospot (ELISPOT) assay, which revealed long-term T 142 cell responses that were ZIKV-and DENV-specific to NS3 protease but cross-reactive 143 to NS3 helicase in individuals infected with DENV and African ZIKV (27) . The impact of 144 cross-reactive immune responses in protection or development of In this study, we utilized our NS1-based ELISAs to determine the DENV and 147 ZIKV serostatus of individuals from Salvador, Brazil, a DENV-hyperendemic region with 148 one of the highest incidence rates of ZIKV during the 2015-16 epidemic (28) . We then 149 tested the ability of our LFn ELISPOT assay to distinguish infections by DENV and 150
Asian ZIKV based on T cells and to characterize those responses. and DENV-E IgG was performed, revealing a high incidence of ZIKV infection in 160 presumed DENV-immune and -naïve individuals (28) . Fifty of these patients were 161 8 included in the present study. Their median age was 43 (range: 23-72), 49% female, 162 and 76% were human immunodeficiency virus (HIV)-infected. All HIV-infected 163 individuals were on antiretroviral therapy; more than 92% had undetectable viral loads 164 and normal CD4 counts. Patient characteristics and acute serology data are 165 summarized in Table S1 and Table 1 , respectively. 166 In order to determine the DENV and ZIKV serostatus among the study 167 participants who had potentially been dual exposed, we collected late convalescent-168 phase blood samples and employed our previously developed . For samples positive for DENV-NS1, we calculated the ratio of 170 relative optical density (rOD) of ZIKV-NS1 to that of DENV-NS1 and used the rOD ratio 171 < or ≥ 0.24 to determine sDENV or ZIKVwpDENV infection, respectively (22 ZIKVwpDENV, and undetermined cases. Using a NS3 protease to helicase ratio cutoff 204 of 1.05 for the IFN-γ ELISPOT, pDENV and sDENV cases and pZIKV, ZIKVwpDENV 205 and the 3 out of the 4 serologically undetermined cases appeared to group together 206 ( Fig. 2A ). From the undetermined cases, 3 out of 4 (ZK1004, 1005, 1008) grouped with 207 the ZIKV-exposed individuals, while ZK0981 grouped with the DENV-infected 208 individuals. Using a ratio cutoff of 1.048 for the TNF-α ELISPOT, similar groupings were 209 observed ( Fig. 2B ). We were unable to distinguish sequential infections based on T cell 210 responses to NS3 protease and helicase. 211
Test data were further analyzed to define sensitivity (identifying true positives; 212 individuals who had been infected by DENV versus ZIKV) and specificity (true NS3-Helicase (LFn-ZV NS3-H). Individuals with pDENV and sDENV infections elicited 236 similar IFN-γ and TNF-α T cell response patterns ( Fig. 3 A-B ). These individuals had T 237 cell responses to LFn-DV NS3-H and LFn-ZV NS3-H that were stronger in magnitude 238 than to LFn-DV NS3-P and LFn-ZV NS3-P, respectively. Additionally, T cell responses 239
to LFn-DV NS3-P and NS3-H were stronger compared to LFn-ZV NS3-P and NS3-H. 240
The amount of T cell cross-reaction to the ZIKV structural proteins (LFn-ZV C and LFn-241 ZV prM) was limited, compared to high cross-reactivity to LFn-ZV NS3-P and NS3-H. to LFn-ZV NS3-H than to the ZIKV structural proteins, TNF-α responses to the ZIKV 247 structural proteins were stronger than to LFn-ZV NS3-P. 248
We further evaluated the impact of DENV immunity on the magnitude of T cell 249 responses. We compared the magnitude of the IFN-γ and TNF-α T cell responses 250 between individuals with pDENV and sDENV infections and pZIKV and ZIKVwpDENV We also compared the magnitude of the IFN-γ and TNF-α T cell responses in 262 DENV-exposed (grouping individuals with pDENV and sDENV infections together), 263 pZIKV, and ZIKVwpDENV individuals who were HIV-negative or HIV-infected. DENV-264 exposed HIV-negative individuals had stronger IFN-γ responses to LFn-ZV C, -ZV NS3-265 P, and -ZV NS3-H compared to HIV-infected individuals. IFN-γ responses to LFn-DV 266 NS3-P and NS3-H appeared to be stronger in the HIV-infected individuals, although 267 these differences were not statistically significant (p=0.61 and p=0.13, respectively) 268 ( Fig. 4 A) . A similar pattern of responses was observed for TNF-α ( Fig. 4 D) . In general, 269
ZIKVwpDENV HIV-negative individuals had stronger IFN-γ and TNF-α responses 270 compared to individuals that were HIV-infected ( Fig. 4 B We report on the characterization of late convalescent-phase antibody and T cell 279 responses in individuals from Salvador, Brazil, a DENV-hyperendemic region that was 280 burdened by the 2015-2016 ZIKV outbreak. Our study presents three major findings in a 281 serologically-validated group of DENV and/or ZIKV infected individuals. First, IFN-γ and 282
TNF-α T cell response ratios of ZIKV NS3 protease to DENV NS3 protease can 283 discriminate infections in individuals exposed to these viruses. Second, individuals with 284 pDENV and sDENV infections have similar T cell response patterns, with extensive 285 cross-reactivity to ZIKV NS3 helicase, whereas individuals with pZIKV and 286
ZIKVwpDENV infections have strong responses to both ZIKV structural and 287 nonstructural proteins, with high cross-reaction to DENV NS3 helicase. Third, HIV-288 infection is associated with responses that are lower in magnitude in DENV exposed 289
individuals. 290
Our previous study of NS1-based ELISAs on convalescent-phase sera from RT-291 PCR confirmed cases with pZIKV, pDENV, sDENV and ZIKVwpDENV infections 292 showed that sDENV infection panel cross-react to ZIKV-NS1 and the rOD ratio of ZIKV-293 NS1 to DENV-NS1 in IgG ELISA can distinguish sDENV and ZIKVwpDENV infections 294 (22). Since anti-NS1 antibodies may decline over time and become undetectable 295 especially for those with primary infection, we further tested these samples with E 296 protein-based IgG ELISAs and identified four negative samples, five pZIKV and four 297 pDENV infections. All these 13 samples have been verified by neutralization test using 298 NT 90 ≥10 as cutoff based on the CDC guidelines (16), suggesting that ΔrOD based on 299
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ZIKV-E and DENV-E IgG ELISAs can distinguish pZIKV and pDENV infections; this 300 could potentially be a useful tool for epidemiology and pathogenesis study in endemic 301 regions. However, the sample size is small and the ΔrOD of 0.17 was based on a single 302 serum dilution of 1:800, future studies involving larger sample size and different 303 dilutions or end-point titers are needed to further validate these observations. 304
The degree of amino acid sequence identity between DENV and ZIKV structural 305 and nonstructural proteins is 49% and 51%, respectively (10). Multiple sequence 306 alignment and homology determination of DENV and ZIKV NS3 demonstrates high 307 amino acid sequence identity of 67%, with protease and helicase homology of 58% and 308 72%, respectively, consistent with the higher degree of DENV/ZIKV cross-reaction in 309 NS3 helicase (Table 3, infected with DENV and Asian ZIKV are in agreement with our previous observations. 314
Although we were unable to distinguish sequential exposure, the LFn NS3 protease 315
ELISPOT differentiates infections between DENV-and ZIKV-infected individuals with 316
high sensitivity and specificity of 94% and 92%, respectively. 317
A relatively large body of epidemiological and laboratory-based evidence has 318 suggested that severe and often fatal forms of dengue disease occurs most commonly 319 during a secondary infection by a heterotypic DENV serotype (29, 30) . Another 320 phenomenon, known as original antigenic sin (OAS), has been observed in antibody as 321
well as T-cell responses, in which less-effective T cells generated in response to a 322 15 primary DENV infection predominate during a subsequent infection with a different 323 DENV serotype, resulting in an inappropriate response and predisposing individuals to 324 severe disease (31, 32) . The OAS hypothesis was challenged by a study in Sri Lankan 325 individuals infected with DENV, which showed that the phenomenon does not generate 326 less functional responses, but instead correlates with protective responses to conserved 327 viral sequences (26). Unexpectedly, we did not observe T cell responses that were 328 significantly higher in magnitude in individuals with prior DENV exposure. These results 329 are in contrast to our data on African ZIKV infections, which showed that previous 330 flavivirus exposure was associated with enhanced T cell responses (27). One possibility 331
is that the proportion of HIV infection among those with prior DENV exposure was 332 higher compared with DENV-naïve in this study (90.5% versus 50% comparing sDENV 333 and pDENV cases; 83.3% versus 60% comparing ZIKVwpDENV and pZIKV cases). 334
Nevertheless, as co-circulation of DENV, ZIKV, and other flaviviruses occurs throughout 335 many parts of the world, it is critical to continue to develop tools to better understand T 336 cell immunity in individuals exposed to multiple flaviviruses. with strong responses to structural and nonstructural proteins. It is noteworthy that we 367
observed comparably strong T cell responses to the structural proteins in pZIKV and 368
ZIKVwpDENV cases, in contrast to Grifoni et al., suggesting that the most recent 369 infection may dictate the T cell response (10). Another possibility that cannot be 370 excluded is the differences in T cell stimulation strategies, which may be contributing to 371 the observed differences. Additionally, due to the limited collection of blood samples 372 from each patient, we were unable to characterize CD4-and CD8-specific responses. 373
Future characterization studies using the LFn delivery system on CD4 and CD8 T cells 374 will be important. DENV infection (44, 45) . In this study, we demonstrated that DENV-exposed individuals 381 who are HIV-infected had T cell responses that were significantly lower in magnitude 382 compared to HIV-negative individuals except in individuals with pZIKV infections. We 383 also observed that DENV-exposed HIV-infected individuals have T cell responses that 384 were lower in magnitude to ZIKV proteins compared to DENV-exposed HIV-negative 385 individuals. Whether HIV infection in DENV-exposed individuals reduces the ability to 386 well followed by incubation for 48 h (except 70 h for DENV1), removal of medium, and 457 fixation as described previously (46). After adding murine mAb 4G2 and secondary 458 antibody mixture (IRDye® 800CW-conjugated goat anti-mouse IgG at 1:10000 and 459 21 DRAQ5™ Fluorescent Probe at 1:10000), the signal (800 nm/700 nm fluorescence) was 460 detected by Li Cor Odyssey classic (LiCor Biosciences) and analyzed by Image Studio 461 software to determine percent neutralization at different concentrations and NT 90 as 462 described previously (46, 48) . Louis, MO, USA) in PBS and washed 6 times with PBS. Cryopreserved PBMCs were 497 thawed in R10 medium and incubated overnight at 37C. PBMCs were washed 2 times 498 with PBS and seeded at 2 x 10 5 cells/well in a final volume of 100ul/well. LFn-DENV 499 and -ZIKV proteins were added to each well. As a positive control, PBMCs were 500 stimulated with phytohemagglutinin ([PHA], Sigma-Aldrich, St. Louis, MO, USA). As a 501 negative control, wells received LFn. After incubation for 24-28 hours at 37C in 5% 502 CO 2 , the cells were discarded and plates were washed 3 times with PBS and 3 times 503 with PBS with 0.05% Tween-20 ([PBST], Bio Rad Technologies, Hercules, CA, USA) to 504 remove cells. The detection antibodies were added and plates were incubated overnight 505 23 at 4C. Plates were then washed 6 times with PBST, then incubated for 2 hours at room 506 temperature with mixtures containing the enzymatic conjugates. To develop spots, 507 plates were washed 4 times with PBST, three times with PBS, and 1 time with water. 508
Vector Blue substrate solution (Vector Laboratories, Burlingame, CA, USA) was added 509
for 5-15 mins before rinsing with water and air-drying. Digitized images were analyzed 510 for spots using CTL ImmunoSpot reader (Cellular Technology Limited, Cleveland, OH, 511 USA). DENV and ZIKV spots were calculated by subtracting the mean of the negative 512 control value from the mean value of the specific stimulation. Positive responses had to 513 be greater than 4 times the mean background, 3 standard deviations above the 514 background, and 55 spot-forming cells per (SFC)/10 6 PBMCs. 515
516

ROC analysis 517 518
The ELISPOTs were validated using PBMCs from individuals that were 519 confirmed DENV-and/or ZIIV-infected by ELISA and/or neutralization tests. DENV and 520 ZIKV NS3 protease to helicase values were calculated, resulting in normalized test 521 ratios (ZIKV NS3 protease divided by DENV NS3 protease) ranging from 0.15-2.95. On 522 the basis of these data, we determined the optimal cutoffs between 0.15 and 2.95 by 523 calculating the sensitivity (number of true positives divided by total confirmed positive 524 values) and specificity (number of true negatives divided by the total confirmed 525 negatives) at increasing 0.05 to the theoretical cutoffs. After calculating the sensitivity 526
and specificity values, the optimal cutoffs were defined as the highest sum of sensitivity 527
and specificity, such that the optimal cutoff values reflected the optimal sensitivity and 528 24 specificity. The optimal cutoffs obtained for the IFN-γ and TNF-α was 1.05 and 1.048, 529 respectively (Prism 7, GraphPad Software, San Diego, CA, USA). PRNT was performed on acute-phase sera to detect neutralization antibody to ZIKV (47).
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c ZIKV-NS1 and DENV-NS IgG ELISAs were described previously (12). The rOD ratio (ZIKV-NS1/DENV-NS1) < or ≥0.24 was 764 classified as sDENV or ZIKVwpDENV (12). NC_035889.1) and DENV1 (ACO06157.1), DENV2 (JN819419.1), DENV3 (ACY70771.1), and DENV4 (AEW50183.1). 
